- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00893958
Bioequivalency Study of Mycophenolate Mofetil 500 mg Tablets Under Fed Conditions
January 19, 2018 updated by: Roxane Laboratories
A Single Dose, 2-Period, 2-Treatment 2-Way Crossover Bioequivalency Study of Mycophenolate Mofetil 500 mg Tablets Under Fed Conditions
The objective of this study was to prove the bioequivalence of Mycophenolate Mofetil 500 mg tablets under fed conditions.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
39
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Austin, Texas, United States, 78759
- CEDRA Clinical Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening
Exclusion Criteria:
- Positive test for HIV, Hepatitis B, or Hepatitis C. Treatment with known enzyme altering drugs. History of allergic or adverse response to mycophenolate mofetil or any comparable or similar product.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
bioequivalence determined by statistical comparison Cmax
Time Frame: baseline, 2-period, 14 day washout
|
baseline, 2-period, 14 day washout
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: William Allan Alexander, M.D., CEDRA Clinical Research
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2006
Primary Completion (Actual)
January 1, 2006
Study Completion (Actual)
January 1, 2006
Study Registration Dates
First Submitted
May 4, 2009
First Submitted That Met QC Criteria
May 5, 2009
First Posted (Estimate)
May 6, 2009
Study Record Updates
Last Update Posted (Actual)
January 23, 2018
Last Update Submitted That Met QC Criteria
January 19, 2018
Last Verified
January 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MYCO-T500-PVFD-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prophylaxis of Organ Rejection
-
Roxane LaboratoriesCompletedProphylaxis of Organ RejectionUnited States
-
Roxane LaboratoriesCompletedProphylaxis of Organ RejectionUnited States
-
Roxane LaboratoriesCompletedProphylaxis of Organ RejectionUnited States
-
Direct Biologics, LLCAvailableSolid Organ Transplant Rejection | Organ Rejection Transplants | Organ RejectionUnited States
-
Guangdong Hengrui Pharmaceutical Co., LtdRecruitingPrevention of Graft Rejection After Organ TransplantationChina
-
Edward GeisslerExcelya; Chiesi Pharmaceuticals GmbHActive, not recruitingProphylaxis Against Liver Transplant RejectionGermany
-
Talaris Therapeutics Inc.TerminatedTransplanted Organ RejectionUnited States
-
Fuzhou General HospitalFudan University; First Affiliated Hospital, Sun Yat-Sen University; RenJi Hospital and other collaboratorsUnknownOrgan Transplant RejectionChina
-
Medical University of ViennaMedical University InnsbruckCompletedAntibody-mediated Rejection | Late Rejection of Renal TransplantAustria
-
Auritec PharmaceuticalsNational Institute of Allergy and Infectious Diseases (NIAID)CompletedPsoriasis | Organ Transplant RejectionUnited States
Clinical Trials on Mycophenolate Mofetil
-
University of GiessenNovartis; Hoffmann-La Roche; Astellas Pharma Inc; Heidelberg UniversityCompletedPolyomavirus InfectionsGermany
-
Novartis PharmaceuticalsCompletedRenal TransplantationUnited States
-
Nanjing University School of MedicineCompletedNephritis | Henoch-Schoenlein PurpuraChina
-
Children's Hospital of Fudan UniversityShanghai Children's Hospital; Shanghai Children's Medical Center; Xinhua Hospital...WithdrawnSteroid-Dependent Nephrotic Syndrome | Frequently Relapsing Nephrotic SyndromeChina
-
Nanjing University School of MedicineCompletedVasculitis | Anti-Neutrophil Cytoplasmic AntibodyChina
-
Teva Branded Pharmaceutical Products R&D, Inc.ParexelTerminatedStable Renal Transplant Recipients
-
Panacea Biotec LtdCompletedHealthy VolunteersIndia
-
Panacea Biotec LtdCompletedHealthy VolunteersIndia
-
Fred Hutchinson Cancer CenterUniversity of WashingtonCompleted
-
Samsung Medical CenterUnknown